Multimodal pooled Perturb-CITE-seq screens in patient models define mechanisms of cancer immune evasion

在患者模型中,多模态混合 Perturb-CITE-seq 筛选揭示了癌症免疫逃逸的机制

阅读:9
作者:Chris J Frangieh # ,Johannes C Melms # ,Pratiksha I Thakore # ,Kathryn R Geiger-Schuller # ,Patricia Ho ,Adrienne M Luoma ,Brian Cleary ,Livnat Jerby-Arnon ,Shruti Malu ,Michael S Cuoco ,Maryann Zhao ,Casey R Ager ,Meri Rogava ,Lila Hovey ,Asaf Rotem ,Chantale Bernatchez ,Kai W Wucherpfennig ,Bruce E Johnson ,Orit Rozenblatt-Rosen ,Dirk Schadendorf ,Aviv Regev ,Benjamin Izar

Abstract

Resistance to immune checkpoint inhibitors (ICIs) is a key challenge in cancer therapy. To elucidate underlying mechanisms, we developed Perturb-CITE-sequencing (Perturb-CITE-seq), enabling pooled clustered regularly interspaced short palindromic repeat (CRISPR)-Cas9 perturbations with single-cell transcriptome and protein readouts. In patient-derived melanoma cells and autologous tumor-infiltrating lymphocyte (TIL) co-cultures, we profiled transcriptomes and 20 proteins in ~218,000 cells under ~750 perturbations associated with cancer cell-intrinsic ICI resistance (ICR). We recover known mechanisms of resistance, including defects in the interferon-γ (IFN-γ)-JAK/STAT and antigen-presentation pathways in RNA, protein and perturbation space, and new ones, including loss/downregulation of CD58. Loss of CD58 conferred immune evasion in multiple co-culture models and was downregulated in tumors of melanoma patients with ICR. CD58 protein expression was not induced by IFN-γ signaling, and CD58 loss conferred immune evasion without compromising major histocompatibility complex (MHC) expression, suggesting that it acts orthogonally to known mechanisms of ICR. This work provides a framework for the deciphering of complex mechanisms by large-scale perturbation screens with multimodal, single-cell readouts, and discovers potentially clinically relevant mechanisms of immune evasion.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。